88.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$87.16
Offen:
$87.17
24-Stunden-Volumen:
1.65M
Relative Volume:
1.04
Marktkapitalisierung:
$42.51B
Einnahmen:
$9.93B
Nettoeinkommen (Verlust:
$1.12B
KGV:
39.40
EPS:
2.25
Netto-Cashflow:
$1.58B
1W Leistung:
+3.15%
1M Leistung:
+3.82%
6M Leistung:
-0.14%
1J Leistung:
-2.36%
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
2025-05-14 | Bestätigt | BTIG Research | Buy |
2025-03-28 | Bestätigt | Needham | Buy |
2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
2025-01-24 | Bestätigt | Needham | Buy |
2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
2024-12-17 | Bestätigt | Needham | Buy |
2024-11-12 | Bestätigt | Needham | Buy |
2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
2024-04-10 | Eingeleitet | Goldman | Buy |
2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2024-01-23 | Eingeleitet | Bernstein | Outperform |
2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
2023-12-12 | Eingeleitet | Stifel | Buy |
2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
2022-12-22 | Eingeleitet | Mizuho | Buy |
2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
2022-04-08 | Eingeleitet | Needham | Buy |
2022-03-11 | Eingeleitet | BofA Securities | Buy |
2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-10-01 | Eingeleitet | Oppenheimer | Perform |
2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-03-26 | Hochstufung | Argus | Hold → Buy |
2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
2020-03-13 | Hochstufung | UBS | Neutral → Buy |
2020-03-05 | Eingeleitet | Citigroup | Neutral |
2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
2020-01-08 | Eingeleitet | Argus | Hold |
2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
2019-06-14 | Eingeleitet | BTIG Research | Neutral |
2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
What analysts say about Alcon Inc. stockDynamic profit opportunities - Autocar Professional
What drives Alcon Inc. stock priceFree Trading Strategy Suggestions - jammulinksnews.com
Is Alcon Inc. a good long term investmentFree Consultation - jammulinksnews.com
Alcon Helps with Back-to-School Prep - MyStateline
RBC Sticks With Alcon As Equipment Sales Lead Growth - Finimize
Swiss Stocks Slip As Roche And Alcon Weigh On The Index - Finimize
Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders - Yahoo Finance
Alcon Inc. Stock Analysis and ForecastRapid profit acceleration - Autocar Professional
September 19th Options Now Available For Alcon (ALC) - Nasdaq
Alcon Stock Gains Following UNITY VCS' Approval in Canada - MSN
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times Europe
Stifel Nicolaus Sticks to Their Buy Rating for Alcon (ALC) - The Globe and Mail
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com Nigeria
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target By Investing.com - Investing.com South Africa
Alcon Adds Noninvasive Treatment Solution, Acquires LumiThera | Business | Jul 2025 - Photonics Spectra
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - VisionMonday.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon’s vitreoretinal-cataract system receives Health Canada approval By Investing.com - Investing.com South Africa
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon’s vitreoretinal-cataract system receives Health Canada approval - Investing.com
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Nasdaq
La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada - New Castle News
Alcon Eyes Vitreoretinal Surgery Market Expansion in LumiThera Deal - MarketScreener
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com Australia
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
Alcon's Bold Bet on Light Therapy: A New Dawn for Dry AMD and Retinal Dominance - AInvest
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
Alcon To Acquire LumiThera And Its Photobiomodulation Device - Nasdaq
Alcon to acquire LumiThera and its dry AMD light therapy device By Investing.com - Investing.com South Africa
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):